CA2198875C - Compositions pharmaceutiques a base de quinazolinone et leur utilisation - Google Patents

Compositions pharmaceutiques a base de quinazolinone et leur utilisation Download PDF

Info

Publication number
CA2198875C
CA2198875C CA002198875A CA2198875A CA2198875C CA 2198875 C CA2198875 C CA 2198875C CA 002198875 A CA002198875 A CA 002198875A CA 2198875 A CA2198875 A CA 2198875A CA 2198875 C CA2198875 C CA 2198875C
Authority
CA
Canada
Prior art keywords
carbon atoms
group
hydrogen
compound
lower alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002198875A
Other languages
English (en)
Other versions
CA2198875A1 (fr
Inventor
Arnon Nagler
Shimon Slavin
Israel Vlodavsky
Mark Pines
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11083194A external-priority patent/IL110831A/en
Application filed by Hadasit Medical Research Services and Development Co, Agricultural Research Organization of Israel Ministry of Agriculture filed Critical Hadasit Medical Research Services and Development Co
Publication of CA2198875A1 publication Critical patent/CA2198875A1/fr
Application granted granted Critical
Publication of CA2198875C publication Critical patent/CA2198875C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique conçue pour empêcher la resténose par inhibition de la prolifération des cellules des muscles lisses, qui comprend un composé de la formule (I) dans lequel: R1 est un membre du groupe constitué d'hydrogène, halogène, nitro, benzo, alkyle inférieur, phényl et alcoxyle inférieur; R2 est un membre du groupe constitué d'hydroxy, acétoxy, et alcoxyle inférieur, et R3 est un membre du groupe constitué d'hydrogène et d'alkénoxy-carbonyle inférieur agissant comme principe actif en association avec un véhicule acceptable sur le plan pharmaceutique.
CA002198875A 1994-08-31 1995-08-29 Compositions pharmaceutiques a base de quinazolinone et leur utilisation Expired - Fee Related CA2198875C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL110831 1994-08-31
IL11083194A IL110831A (en) 1994-08-31 1994-08-31 Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
PCT/US1995/011186 WO1996006616A1 (fr) 1994-08-31 1995-08-29 Compositions pharmaceutiques a base de quinazolinone et leur utilisation

Publications (2)

Publication Number Publication Date
CA2198875A1 CA2198875A1 (fr) 1996-03-07
CA2198875C true CA2198875C (fr) 2005-11-15

Family

ID=35530890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002198875A Expired - Fee Related CA2198875C (fr) 1994-08-31 1995-08-29 Compositions pharmaceutiques a base de quinazolinone et leur utilisation

Country Status (1)

Country Link
CA (1) CA2198875C (fr)

Also Published As

Publication number Publication date
CA2198875A1 (fr) 1996-03-07

Similar Documents

Publication Publication Date Title
AU692307B2 (en) Quinazolinone pharmaceuticals and use thereof
US6159488A (en) Intracoronary stents containing quinazolinone derivatives
US5891879A (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
WO1996006616A9 (fr) Compositions pharmaceutiques a base de quinazolinone et leur utilisation
CA2253362C (fr) Extenseurs intracoronariens contenant des derives quinazolinone
Berk et al. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty
JPH11503911A (ja) 動静脈及び静脈の移植治療：方法及び組成物
Choi et al. Halofuginone, a specific collagen type I inhibitor, reduces anastomotic intimal hyperplasia
EP0794780B1 (fr) Compositions pharmaceutiques contenant de la quinazolinone et leurs procedes d'utilisation
EP0831807B1 (fr) Utilisation de brefeldine a et de ses derives dans le preparation des medicaments pour le traitement de l'hyperplasie et de troubles apparentes
Nagler et al. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone
USRE39096E1 (en) Treatment of skin disorders
EP1210086B1 (fr) Utlisation du halofuginone dans le traitement du retrecissement de l'uretre
Halloran et al. Platelet-derived growth factor is a cofactor in the induction of 1α (I) procollagen expression by transforming growth factor β1 in smooth muscle cells
US5998422A (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
Karim et al. In VivoRole of Glucocorticoids in Barotrauma Vascular Repair and Fibrosis
Asada et al. Suramin inhibits intimal thickening following intimal injury in the rabbit aorta in vivo
Nagaura et al. Basic fibroblast growth factor stimulates the competence phase of subcultured endothelial cells and the progression phase of primary cultured smooth muscle cells from rat aorta
JP2000191540A (ja) 再狭窄薬物療法
Poorkhalkali et al. Cell kinetics of the oesophageal epithelium in the rat: effects of hypergastrinaemia
Zvibel et al. Synergies of heparin and second messengers pathways involved in tissue-specific gene expression in hepatocytes
長浦健 et al. Basic Fibroblast Growth Factor Stimulates the Competence Phase of Subcultured Endothelial Cells and the Progression Phase of Primary Cultured Smooth Muscle Cells from Rat Aorta.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed